Valneva (NASDAQ:VALN) Shares Gap Up – What’s Next?

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped up prior to trading on Monday . The stock had previously closed at $5.05, but opened at $5.28. Valneva shares last traded at $5.2410, with a volume of 7,045 shares.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Wall Street Zen raised shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a report on Wednesday, April 22nd. Finally, Guggenheim set a $11.00 price objective on shares of Valneva in a research report on Thursday, April 16th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $11.97.

Valneva Price Performance

The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14. The stock has a market capitalization of $484.89 million, a price-to-earnings ratio of -2.73 and a beta of 1.77. The business’s 50 day simple moving average is $5.54 and its 200-day simple moving average is $7.60.

Valneva (NASDAQ:VALN) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The firm had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. Research analysts anticipate that Valneva SE Sponsored ADR will post -1 earnings per share for the current year.

Institutional Trading of Valneva

Several hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new position in Valneva during the 4th quarter worth $44,000. JPMorgan Chase & Co. acquired a new position in shares of Valneva during the third quarter valued at $124,000. XTX Topco Ltd acquired a new position in shares of Valneva during the fourth quarter valued at $94,000. Finally, Marex Group plc bought a new stake in shares of Valneva during the second quarter valued at about $64,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.